Sensus Healthcare Q1 2026: Transition Underway as CPT Codes Take Effect, But Revenue Drops on Large Customer Absence

What happened

Sensus Healthcare's first quarter of 2026 marked the start of a new reimbursement era with dedicated CPT codes for superficial radiotherapy, but the company's revenue fell versus the prior year primarily because its historically largest customer made no purchases. Management framed the quarter as a transition period, but the absence of the dominant customer underscores the extreme concentration risk that remains unaddressed. While the new CPT codes theoretically improve physician economics and could drive demand, there is no evidence yet of a tangible order uptick or diversification away from the one large account. Gross margins and profitability are still under pressure from the Fair Deal model and service costs, and the legal overhang from 2025 investigations persists. The Q1 results offer no confirmation of a turnaround, reinforcing that execution on the CPT tailwind and channel diversification is still unproven.

Implication

The Q1 2026 earnings confirm that Sensus remains in a high-risk transition period where the new CPT codes have not yet translated into revenue growth or reduced customer concentration. The absence of orders from the largest customer is a stark reminder that the company's financial performance is still at the mercy of one buyer, and the diversification efforts via Fair Deal, ROS oncology, and international channels are still too small to offset a loss. The bull case depends on rapid adoption of SRT under the better reimbursement, but Q1 provides no evidence of that inflection. The bear case remains plausible: the large customer may permanently reduce purchases, and the CPT tailwind may fail to generate enough incremental demand to restore growth and profitability. With the stock near $4.99 and a base-case value of $6, the risk/reward is unattractive given the lack of near-term catalysts. Our WAIT rating is affirmed, and we recommend waiting for at least one quarter of confirmatory data before considering a position. The $3 bear-case scenario is still in play if the large customer continues to withhold orders and other channels fail to fill the gap.

Thesis delta

The thesis is unchanged: the investment case hinges on the new CPT codes driving a material acceleration in system orders and Fair Deal utilization, while reducing reliance on a single large customer. Q1 2026 offered no evidence of this inflection, and the absence of the largest customer's orders highlights the persistent vulnerability. The thesis remains unconfirmed, and the wait-and-see approach is validated.